Ariad Pharmaceuticals, Inc. (ARIA) Announces Initial Data from Phase 2 Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors
6/2/2014 9:16:05 AM
CAMBRIDGE, Mass. & CHICAGO--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced, for the first time, data from its Phase 2 trial of Iclusig® (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST). The initial data show that ponatinib has anti-tumor activity in patients with advanced GIST, particularly in patients with KIT exon 11 mutations, after failure of at least one prior tyrosine kinase inhibitor (TKI). The primary endpoint for the trial, clinical benefit rate (CBR) at 16 weeks for patients with KIT exon 11 mutations, was 50 percent, with a median follow-up of six months.
Help employers find you! Check out all the jobs and post your resume.
comments powered by